A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.

Xin TangYuan LiWen-Lei QianWei-Feng YanTong PangYou-Ling GongZhi Gang Yang

Published in: Journal of cancer research and clinical oncology (2021)

PFS of the prior EGFR-TKI treatment, performance status score and bone metastasis were independent prognosticators of the osimertinib treatment. These findings may facilitate clinicians in the decision-making of osimertinib.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
tyrosine kinase
replacement therapy